Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
Open Access
- 11 November 2019
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 38 (2) , 205-216
Abstract
Background An increasing number of technologies are obtaining marketing authorisation based on sparse evidence, which causes growing uncertainty and risk within health technology reimbursement decision making. To ensure that uncertainty is considered and addressed within health technology assessment (HTA) recommendations, uncertainties need to be identified, included in health economic models, and reported. Objective Our objective was to develop the TRansparent Uncertainty ASsessmenT (TRUST) tool for systematically identifying, assessing, and reporting uncertainties in decision models, with the aim of making uncertainties and their impact on cost effectiveness more explicit and transparent. Methods TRUST was developed by drawing on the uncertainty and risk assessment literature. To develop and validate this tool, we conducted HTA stakeholder discussion meetings and interviews and applied it in six real-world HTA case studies in the Netherlands and the UK. Results The TRUST tool enables the identification and categorisation of uncertainty according to its source (transparency issues, methodology issues, and issues with evidence: imprecision, bias and indirectness, and unavailability) in each model aspect. The source of uncertainty determines the appropriate analysis. The impact of uncertainties on cost effectiveness is also assessed. Stakeholders found using the tool to be feasible and of value for transparent uncertainty assessment. TRUST can be used during model development and/or model review. Conclusion The TRUST tool enables systematic identification, assessment, and reporting of uncertainties in health economic models and may contribute to more informed and transparent decision making in the face of uncertainty.Keywords
Funding Information
- ZonMw (1520020521, 531002051)
This publication has 34 references indexed in Scilit:
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated ApprovalJAMA Internal Medicine, 2019
- The Cancer Drugs Fund in Practice and Under the New FrameworkPharmacoEconomics, 2019
- Implementing managed entry agreements in practice: The Dutch reality checkHealth Policy, 2019
- Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics, 2018
- EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and UncertaintiesApplied Health Economics and Health Policy, 2018
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13BMJ, 2017
- Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?Clinical Pharmacology & Therapeutics, 2015
- Healthy Decisions: Towards Uncertainty Tolerance in Healthcare PolicyPharmacoEconomics, 2014
- Exploring Uncertainty in Cost-Effectiveness AnalysisPharmacoEconomics, 2008
- Handling Uncertainty in Cost-Effectiveness ModelsPharmacoEconomics, 2000